Luspatercept for Patients With Lower-Risk MDS: Data from the COMMANDS Trial

Dr Amer Zeidan details the design, patient population, and key efficacy and safety data from the phase 3 COMMANDS trial investigating luspatercept for the frontline treatment of lower-risk MDS with anemia.

EP: 1.Diagnosing Lower-Risk Myelodysplastic Syndromes (LR-MDS)

EP: 2.Risk Stratification in MDS

EP: 3.Historical First-Line Treatment Options for Lower-Risk MDS With Symptomatic Anemia

Now Viewing

EP: 4.Luspatercept for Patients With Lower-Risk MDS: Data from the COMMANDS Trial

EP: 5.Clinical Implications of the COMMANDS Trial in the Treatment of Lower-Risk MDS

Recent Videos